BioCheck is a patented and easy-to-use screening kit that combines a 'best in class' protein assay with a pH test to rapidly assess suspicious powders representing potential biological threats. Emergency responder teams and government agencies worldwide have used the sensitive kits for more than seven years.

Jonathan Cohen, President & CEO of 20/20 BioResponse, a division of 20/20 GeneSystems Inc., said: "Smiths Detection is an ideal partner with a well-established global customer base that will greatly benefit from the capabilities that BioCheck offers. Their full breadth of complementary technologies provides a comprehensive solution, and we look forward to a meaningful and long-term relationship with them."